You just read:

Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer

News provided by

Daiichi Sankyo Company, Limited

Jan 18, 2017, 08:00 ET